

## Co-Diagnostics, Inc. COVID-19 Test Technology Validated for Use on Saliva Samples

---

**Salt Lake City, Utah - April 16, 2020** - Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that OralDNA® Labs, a CLIA-certified laboratory, has recently validated a COVID-19 PCR test based on the Company's patented CoPrimer™ technology for use with saline oral rinse samples, and has notified the FDA of their intent to use the validated test in their CAP accredited high-complexity laboratory.

Dwight Egan, Co-Diagnostics CEO, remarked "This validation on the OraRisk® line of salivary diagnostics showcases the versatility and flexibility of our CoPrimer platform and COVID-19 test. Saliva specimens are easily collected with a simple swish and gargle, as opposed to more invasive collection methods such as nasal swabs. We are pleased that our technology is being deployed in so many areas in the United States and countries across the world, providing the type of quality, high-throughput diagnostic solutions that many experts agree is the most important step to curbing the spread of COVID-19 and saving lives."

The Company's Logix Smart™ COVID-19 test is currently available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA), and is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes COVID-19.

OralDNA® Labs' original release may be found [here](#).

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

### Forward-Looking Statements

**This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company's products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company's balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.**

### Company Contact:

Andrew Benson  
Co-Diagnostics Investor Relations  
801-438-1036  
[investors@codiagnostics.com](mailto:investors@codiagnostics.com)

or

### Media Contact:

Jennifer Webb  
Coltrin & Associates, Inc  
+1.267.912.1173

[jennifer\\_webb@coltrin.com](mailto:jennifer_webb@coltrin.com)

---

<https://news.codiagnosics.com/2020-04-16-Co-Diagnostics-Inc-COVID-19-Test-Technology-Validated-for-Use-on-Saliva-Samples>